Share
Is OAT approval required to prescribe buprenorphine formulations other than buprenorphine/naloxone for the treatment of opioid use disorder (OUD)?
No. An OAT approval is not required for prescribing buprenorphine for OAT, irrespective of formulation type.
Other formulations of buprenorphine for OAT include Sublocade®, extended-release buprenorphine injection, and Probphine®, subdermal buprenorphine implant.
While an OAT approval is not required, we expect physicians to to complete certification and training recommended by drug manufacturers for these products. Please refer to the respective product monographs for more information.
Buprenorphine OAT formulations are TPP type 2 drugs, and as such, do not require a TPP form or TPP registration to be prescribed.